COMMUNIQUÉS West-GlobeNewswire

ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
15/10/2026
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield No Thromboembolic Events Were Reported for ADMA IVIG Products Manufactured [...]
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
15/10/2026
BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced an [...]
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
15/10/2026
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months Initiation and [...]
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
15/10/2026
Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of [...]
Affidea signs agreement to acquire two Alliance Medical centres in central London, accelerating its UK growth
15/10/2026
LONDON, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Affidea , a leading pan-European provider of community-based clinics, advanced diagnostics and specialist private healthcare services has signed an agreement to acquire two [...]
Osivax Reports Phase 2b Results for OVX836 and Advances Combination Strategy for Next-Generation Seasonal Influenza Vaccines
15/10/2026
Phase 2b study provides first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes OVX836 did not meet its pre-specified primary endpoint of 50% [...]
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
15/10/2026
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal Publication in Molecular Therapy Oncology reports Phase 1 data from 17 patients with advanced, treatment- [...]
EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
15/10/2026
October 15, 2026 Five-year research project unites 42 public and private partners across 17 countries to conduct 22 clinical studies involving 14,000+ patients; first patients will be enrolled this month Project aims to [...]
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
15/10/2026
MTX325 is a first-in-class, highly potent, orally bioavailable, brain-penetrant USP30 inhibitor designed to modify the course of Parkinson’s by improving mitochondrial control Phase 1b ‘MTX325-101’ study – taking place [...]
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
15/10/2026
Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercialization Appointment comes as iOnctura prepares for late-stage [...]
DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
15/10/2026
Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis (TB) targets for faster and more cost-effective drug discovery [...]
OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology
15/10/2026
Financing co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with strong participation from additional new and existing investors Proceeds to advance MC2 receptor antagonist OMS1620 through [...]
OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
15/10/2026
Nantes, France, October 15, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and [...]
OSE Immunotherapeutics présentera lors de la 10ème Chardan Annual Healthcare Conference
15/10/2026
Nantes, France, 15 octobre 2026 – 7h30 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnémo: OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie [...]
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
15/10/2026
October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, [...]
IBA selected to support the US expansion of a leading radiopharmaceutical producer with an order for 12 Cyclone® KIUBE systems
15/10/2026
IBA is preferred supplier for a 12-system national PET radiopharmaceutical production network, securing capacity ahead of demand across diagnostics and theranostics Louvain-la-Neuve, Belgium – October 15, 2026, 7 a.m [...]
IBA sélectionnée pour équiper l’expansion aux États-Unis d’un leader de la production de radiopharmaceutiques avec une commande de 12 systèmes Cyclone® KIUBE
15/10/2026
IBA devient le fournisseur privilégié pour équiper de 12 systèmes un réseau national de production de radiopharmaceutiques TEP, sécurisant des capacités de production en anticipation de la demande dans les domaines du [...]
Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026
15/10/2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases 2026 annual guidance The company reports 40% year-over-year increase in sales in the first nine months of 2026 Schlieren ( [...]
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
15/10/2026
Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 Expected year-over-year growth of approximately 15 [...]

Pages